Profile data is unavailable for this security.
About the company
Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe, and others. In India, the Company sells bulk drugs and intermediates, chemicals, and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
- Revenue in INR (TTM)11.68bn
- Net income in INR3.71bn
- Incorporated2018
- Employees1.17k
- LocationSuven Pharmaceuticals LtdSDE Serene ChambersRoad no. 5, Avenue 7, Banjara hillsHYDERABAD 500081IndiaIND
- Phone+91 4 023549414
- Fax+91 4 023541152
- Websitehttps://www.suvenpharm.com/
More ▼
Mergers & acquisitions
| Acquired company | SUVENPHAR:NSI since announced | Transaction value |
|---|---|---|
| Cohance Lifesciences Ltd | -1.18% | 981.19m |
Data delayed at least 15 minutes, as of May 24 2024 10:59 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wockhardt Ltd | 27.76bn | -5.01bn | 84.96bn | 2.74k | -- | -- | -- | 3.06 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
| Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 99.42bn | 777.00 | 21.86 | 4.29 | 19.31 | 5.87 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | 7.86 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 2.59 |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 100.83bn | 1.82k | 21.44 | 4.32 | 19.23 | 4.42 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Granules India Ltd | 45.06bn | 4.05bn | 104.09bn | 3.65k | 25.67 | 3.23 | 16.99 | 2.31 | 16.73 | 16.73 | 186.06 | 133.08 | 0.8645 | 1.65 | 4.66 | -- | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 51.39 | 8.99 | 11.82 | 0.7706 | 6.13 | 0.2896 | 7.84 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Jubilant Pharmova Ltd | 66.22bn | 378.60m | 113.66bn | 1.03k | 296.22 | -- | 19.39 | 1.72 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
| Eris Lifesciences Ltd | 20.09bn | 3.92bn | 120.44bn | 3.55k | 30.76 | 4.66 | 20.78 | 5.99 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Astrazeneca Pharma India Ltd | 11.97bn | 1.39bn | 141.92bn | 947.00 | 101.88 | -- | 91.72 | 11.86 | 55.72 | 55.72 | 478.78 | -- | -- | -- | -- | 12,640,230.00 | -- | 10.51 | -- | 18.10 | 59.93 | 58.05 | 11.64 | 9.11 | -- | 132.84 | -- | 11.82 | 24.50 | 11.89 | 61.19 | 30.82 | 6.29 | -- |
| Concord Biotech Ltd | 9.71bn | 3.05bn | 152.66bn | -- | 50.74 | -- | 42.57 | 15.73 | 28.76 | 28.76 | 92.74 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.70 | -- | 31.38 | -- | -- | -- | -- | -- | 19.67 | -- | 37.25 | -- | -- | -- |
| Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 160.44bn | 1.17k | 43.24 | -- | 38.20 | 13.74 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
| Piramal Enterprises Ltd | 80.27bn | -16.84bn | 183.08bn | 12.22k | -- | 0.6894 | -- | 2.28 | -76.51 | -76.51 | 345.53 | 1,187.94 | 0.0965 | -- | 497.33 | -- | -2.02 | 2.57 | -2.05 | 3.16 | 45.17 | 81.98 | -20.97 | 21.59 | -- | -0.0035 | 0.6686 | 26.39 | -3.80 | -7.55 | -116.89 | -- | 12.91 | -18.22 |
| Natco Pharma Ltd. | 38.28bn | 12.78bn | 183.61bn | 3.98k | 14.47 | -- | 12.66 | 4.80 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
| Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 188.81bn | 14.59k | 30.65 | 3.92 | 21.23 | 3.03 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | -- | 9.77 | 10.82 | 12.94 | 14.38 | 72.46 | 67.67 | 9.90 | 12.58 | 0.9863 | 11.76 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Piramal Pharma Ltd | 81.71bn | 178.20m | 197.11bn | 6.30k | 2,492.50 | 2.50 | 25.99 | 2.41 | 0.06 | 0.06 | 65.09 | 59.80 | 0.5478 | 1.53 | 4.15 | -- | 0.1195 | -- | 0.1648 | -- | 63.85 | -- | 0.2181 | -- | 0.7527 | 6.74 | 0.3732 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Sanofi India Ltd | 28.47bn | 5.49bn | 205.73bn | 2.17k | 37.47 | -- | 34.93 | 7.23 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Pfizer Ltd | 21.93bn | 5.51bn | 209.28bn | 1.70k | 37.96 | 5.82 | 34.11 | 9.54 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Data as of May 24 2024. Currency figures normalised to Suven Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
17.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UTI Asset Management Co. Ltd. (Investment Management)as of 27 Dec 2023 | 12.73m | 5.00% |
| DSP Asset Managers Pvt. Ltd.as of 30 Apr 2024 | 12.04m | 4.73% |
| The Vanguard Group, Inc.as of 09 May 2024 | 4.03m | 1.58% |
| HSBC Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 3.99m | 1.57% |
| Goldman Sachs Asset Management LPas of 29 Feb 2024 | 2.84m | 1.11% |
| Tata Asset Management Ltd.as of 30 Apr 2024 | 2.53m | 1.00% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 1.91m | 0.75% |
| BlackRock Fund Advisorsas of 09 May 2024 | 1.83m | 0.72% |
| Canara Robeco Asset Management Co. Ltd.as of 30 Apr 2024 | 1.68m | 0.66% |
| Axis Asset Management Co. Ltd.as of 30 Apr 2024 | 1.58m | 0.62% |
More ▼
Data from 31 Mar 2024 - 15 May 2024Source: FactSet Research Systems Inc.
